DATA DRIVEN APPROACH IN CLINICAL TRIALS

According to NCBI, ~80% of clinical trials fail to meet the initial enrolment target, resulting in significant delays and sunk revenues of ~US $8 Million/day for pharma and biotech companies. Patient recruitment/retention, accurate patient mapping is the #1 challenge in clinical trials.

Discover how a data-driven approach can address such challenges in Finarb’s upcoming session.

Why attend?

Case study discussion: on Sep 28, 9:30 AM PST, join IQVIA, Finarb, Greenphire and Frazier Lifesciences as we delve into industry case studies and explore how enterprises can adopt a data-driven approach and custom AI to advance clinical trials at various stages.

Interact with our speakers: Get your queries addressed about how to get the most out of your data & AI initiatives for clinical trials, how to accurately conduct patient mapping using AI, improve on patient enrolment and retention strategies and the best applications for AI for your organization!

Our speakers: 
JINU JOSE
IQVIA - VP of Clinical Data Management

KEN MCLAREN
FRAZIER HEALTHCARE - Partner for Data & AI

ABHISHEK RAY
FINARB ANALYTICS - Chief of Data Science

Who are attending: 100+ Executive management, R&D heads, Clinical ops leads, Patient recruitment teams, Pharmacovigilance, Regulatory, Drug Discovery teams from Eli Lilly, Pfizer, Novartis, J&J, Merck, Biocon, IQVIA, PPD (now part of Thermofisher), Syneos Health among others.

Agenda:

-Introduction by Finarb
-Insights into the CRO/Pharmaceuticals survey
-IQVIA-How AI ML-driven data management is accelerating clinical trial processes
-Finarb's AI use cases in trial design, patient recruitment & retention, controlling dropouts
-How Frazier LifeSciences portfolio CRO's are applying AI in clinical trials
-Audience Q&A